FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, reviews the venous thromboembolism (VTE) data behind ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Sarah Cannon's Kelsey Martin, APRN, AOCNP, discusses managing toxicities, nursing collaboration, and tailored treatment sequencing in frontline mTNBC. In an era of rapid oncology advancements, ...

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, ...

C, discussed the collaborative care model and the vital role of PAs in managing day-to-day oncology care. Physician ...

Having recently moderated a case-based roundtable discussion on triple-negative breast cancer, Iorio shares her clinical ...

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic ...

Emily Beard discusses how nurse navigators act as essential bridges, leveraging clinical intuition and time to address ...

At the 29th APAO Symposium, Dr. Angela Jia highlighted the critical role of PAs and NPs in managing toxicities and applying ...

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, ...